QIAGEN Shares Outstanding 2006-2021 | QGEN

QIAGEN shares outstanding history from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • QIAGEN shares outstanding for the quarter ending September 30, 2021 were 0.232B, a 1.55% decline year-over-year.
  • QIAGEN 2020 shares outstanding were 0.234B, a 3.28% increase from 2019.
  • QIAGEN 2019 shares outstanding were 0.227B, a 2.86% decline from 2018.
  • QIAGEN 2018 shares outstanding were 0.233B, a 0.19% increase from 2017.
QIAGEN Annual Shares Outstanding
(Millions of Shares)
2020 234
2019 227
2018 233
2017 233
2016 239
2015 239
2014 243
2013 233
2012 232
2011 230
2010 232
2009 206
2008 197
2007 169
2006 148
2005 145
QIAGEN Quarterly Shares Outstanding
(Millions of Shares)
2021-09-30 232
2021-06-30 232
2021-03-31 232
2020-12-31 234
2020-09-30 236
2020-06-30 234
2020-03-31 232
2019-12-31 227
2019-09-30 227
2019-06-30 233
2019-03-31 234
2018-12-31 233
2018-09-30 235
2018-06-30 234
2018-03-31 233
2017-12-31 233
2017-09-30 233
2017-06-30 233
2017-03-31 235
2016-12-31 239
2016-09-30 239
2016-06-30 239
2016-03-31 238
2015-12-31 239
2015-09-30 228
2015-06-30 228
2015-03-31 229
2014-12-31 243
2014-09-30 232
2014-06-30 232
2014-03-31 234
2013-12-31 233
2013-09-30 233
2013-06-30 225
2013-03-31 233
2012-12-31 232
2012-09-30 233
2012-06-30 231
2012-03-31 230
2011-12-31 230
2011-09-30 229
2011-06-30 232
2011-03-31 231
2010-12-31 231
2010-09-30 230
2010-06-30 233
2010-03-31 227
2009-12-31 232
2009-09-30 201
2009-06-30 196
2009-03-31 196
2008-12-31 195
2008-09-30 197
2008-06-30 198
2008-03-31 198
2007-12-31 206
2007-09-30 179
2007-06-30 151
2007-03-31 147
2006-12-31 149
2006-09-30 148
2006-06-30 148
2006-03-31 147
2005-12-31 144
2005-09-30 145
2005-06-30 144
2005-03-31 144
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.053B $1.870B
Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69